Screening: Recommend pre-treatment ophthalmic exam including slit lamp exam and dilated fundoscopic exam. Patient screening for risk factors attributed to the development of severe events (e.g., hypertension, CAD, baseline visual deficits) should be considered before administration of vemurafenib, especially in conjunction with MEK inhibitors. Eye exams may be conducted every 3-6 months to monitor for more severe ocular adverse events.Management: The drug should be discontinued with signs of any serious ocular adverse events and an ophthalmologist should be consulted. The gene discussed is MAP2K7; the disease is Hypertension.